{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$21.3B vs. cons ~$20.5B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP EPS (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$6.10 vs. cons ~$6.55",
      "confidence": "LOW"
    },
    {
      "kpi": "Mounjaro + Zepbound combined revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$15.2B vs. cons ~$14.0B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Revenue guidance",
      "prediction": "BETTER",
      "answer": "guide ~$86-89B vs. cons ~$84B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Non-GAAP EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$33.00-35.50 vs. cons ~$35.50 (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY2026 price/volume mix headwind commentary",
      "prediction": "UNCHANGED",
      "answer": "guide ~-13% price headwind vs. cons ~-13% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.3,
  "day5_path": "FADE",
  "day5_rationale": "Depressed 30/90-day EPS consensus (down ~26%/19%) already reflects fears of heavy acquired-IPR&D/M&A dilution (Orna, Centessa, Kelonia, Ajax, AtaiBeckley), so a revenue/volume beat plus reiterated low-to-mid-teens price headwind should spark an initial relief rally as the bar was set low. But an EPS miss on charges and a lowered (not raised) full-year EPS guide range, alongside no fresh resolution to the capital-allocation overhang (expensive buybacks vs. accelerating BD spend) and the unresolved Novo Nordisk ad litigation, gives analysts room to keep trimming out-period EPS even after a top-line beat \u2014 causing the initial pop to fade over the following days rather than follow through.",
  "day5_confidence": "LOW"
}